Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma
JCO Precision Oncology · 2025-07 · (9)
DOI: 10.1200/po-24-00934 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-07. Verfasst von Maen Abdelrahim und 21 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Hepatocellular carcinoma (HCC) has high relapse rates after standard-of-care (SOC) resection or liver transplantation (LT). We evaluated the utility of circulating tumor DNA (ctDNA) to predict relapse/progression risk in patients with HCC. Materials and Methods This retrospective analysis examined real-world data from ctDNA testing on 125 patients with HCC (721 plasma samples) undergoing curative-intent treatments and SOC management. Patients were divided into four subcohorts: cohort A (n = 64) and B (n = 52) comprised patients under recurrence monitoring after LT or resection, respectively. Cohort C (n = 4) and D (n = 5) comprised patients under treatment response monitoring with known recurrence or inoperable disease, respectively. A personalized, tumor-informed 16-plex polymerase chain reaction next-generation sequencing assay (Signatera, Natera, Inc, Austin, TX) was used for ctDNA testing. The molecular residual disease (MRD) window was defined as 2-12 weeks post-LT/resection (cohorts A/B), before starting adjuvant therapy (AT). Surveillance window was defined as post-MRD window or 2 weeks post-AT (cohort B) or during ongoing treatment (cohorts C/D). RESULTS The median follow-up was 40 (1.5-60) months. In cohort A, 97.2% (35/36) of patients with ctDNA negativity in the MRD window remained negative during surveillance. In cohort B, ctDNA was detected in 29.4% (10/34) of patients within the MRD window, all of whom experienced clinical recurrence (hazard ratio [HR], 7.2 [95% CI, 2.6 to 20]; P < .0001). In the surveillance window (cohort B), the ctDNA detection rate was 32.3% (10/31), and all experienced recurrence (HR, 18.0 [95% CI, 3.9 to 85]; P < .0001). In cohorts C/D, on-treatment ctDNA dynamics were concordant with treatment response as measured by imaging. Compared with alpha-fetoprotein, ctDNA had higher sensitivity and a significantly longer lead time (7.9 v 2.2 months) for recurrence detection. CONCLUSION Serial ctDNA testing effectively identified HCC recurrence early, postresection and post-LT. ctDNA was also useful for treatment response monitoring and could help resolve ambiguous imaging results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston, TX.
- The Liver Institute at Methodist Dallas Medical Center, Dallas, TX.
- Georgetown University Medical Center, Washington, DC.
- The University of Chicago, Chicago, IL.
- Massachusetts General Hospital, Boston, MA.
- JC Walter Jr Center for Transplantation and Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston, TX.
ORCID-Profile: Maen Abdelrahim, Abdullah Esmail, Mahmoud Ouf, Joseph W Franses, Irun Bhan, Ashish Saharia, Amit Mahipal, Nikolas Naleid, Catherine Bridges, Vasily N Aushev, Arkarachai Fungtammasan, J Bryce Ortiz, Adham Jurdi, Minetta C Liu, Aiwu Ruth He
Förderung
- NCI NIH HHS
Zitieren
APA
Abdelrahim, M., Mejia, A., Esmail, A., Barrera Gutierrez, J. C., Ouf, M., Franses, J. W., Bhan, I., Kodali, S., Saharia, A., Mahipal, A., Naleid, N., Bridges, C., Tin, A., Brewer, C. M., Aushev, V. N., Fungtammasan, A., Palsuledesai, C. C., Ortiz, J. B., Jurdi, A., …, & He, A. R. (2025). Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-24-00934
Vancouver
Abdelrahim M, Mejia A, Esmail A, Barrera Gutierrez JC, Ouf M, Franses JW, et al. Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma. JCO Precision Oncology. 2025. doi:10.1200/po-24-00934
BibTeX
@article{Abdelrahim2025,
author = {Abdelrahim, Maen and Mejia, Alejandro and Esmail, Abdullah and Barrera Gutierrez, Juan Carlos and Ouf, Mahmoud and Franses, Joseph W and Bhan, Irun and Kodali, Sudha and Saharia, Ashish and Mahipal, Amit and Naleid, Nikolas and Bridges, Catherine and Tin, Antony and Brewer, Chris M and Aushev, Vasily N and Fungtammasan, Arkarachai and Palsuledesai, Charuta C and Ortiz, J Bryce and Jurdi, Adham and Liu, Minetta C and Ghobrial, R Mark and He, Aiwu Ruth},
title = {Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00934}
}
EUVIMED